Advasence a semiconductor company, completed a $14 million B round of finance,
The capital raised in this round will assist the company in furthering the development and marketing of its product line.

Advasense's innovative CIS (CMOS Image Sensor) technology enables the smallest high performing pixels in the industry. Advasense provides a unique solution to the challenge of blurry and noisy pictures taken by camera phones in low light environments by adding an on chip still image stabilization (that does not require any frame buffer memory) to its CIS products.

Can-Fite, a biotechnology company traded on the Tel Aviv Stock Exchange, successfully completed long-term pre-clinical toxicology studies with its lead drug, CF101. Studies were in full GLP compliance with US FDA and EMEA requirements. The success of these studies will enable patients who participate in future clinical studies with Can-Fite's CF101 to take the drug for periods of 6 -12 months or longer, as generally required in phase III clinical studies.

In January 2007, Can-Fite announced the enrolment of about 250 patients in a phase IIb RA clinical trial in the US, Europe and Israel, in which CF101 was given for a period of 12 weeks. The results of this trial are expected to be released this summer.

The company announced that additional pre-clinical studies are underway to facilitate the initiation of phase III trials shortly after the release of the phase IIb study results. These studies include the development of a new drug formulation, in-vivo assessments of the distribution of radio labeled drug, and others.

Altair Semiconductor, a fabless chip company developing the most advanced mobile WiMAX processor for handsets and handheld devices, recently closed an US$18M Series B funding round led by Bessemer Venture Partners. Bessemer was joined by other existing investors in the company including Giza Venture Capital and brings significant wireless industry experience and global strategic relationships to the company.

Altair is the world's leading developer of ultra-low power, small footprint and high performance mobile WiMAX semiconductors that take broadband bandwidth beyond notebooks and USB adaptors to un-tethered, battery-operated handsets and handheld devices. The company's proprietary ultra-low power Optimized OFDMA Processor (O2P) provides handset manufacturers integrating WiMAX into their products with a robust, cost-effective solution.

Flash Networks, a leading provider of mobile Internet quality-of-experience (QoE) solutions, has been awarded with Network Equipment-Building System (NEBS) Level 3 certification for its NettGain™ solutions. NEBS Level 3 certification is a valuable indicator of quality for companies supplying network equipment to operators in the United States, and is required to provide solutions to all tier 1 regional Bell operators.

NEBS Level 3 certifies that Flash Networks’ equipment can perform well in the harshest environmental conditions and will not interfere with other electronic devices in an operator’s Central Office. The Telecommunications Carrier Group (TCG), consisting of the leading North American operators, created the NEBS checklist to ensure that the equipment procured was reliable and had minimum downtime in the event of an emergency.

In addition to NEBS certification, Flash Networks has also been certified to the International Standards Organization (ISO)’S ISO 9001:2000 standard. This certification demonstrates that Flash Networks’ solutions meet well-defined levels of quality and consistency and is an effective form of differentiation between suppliers.

iamba Networks, a leading provider of gigabit passive optical networking (GPON) solutions and Kawasaki Microelectronics America, Inc. (K-micro), a leader in advanced ASICs, have collaborated on the development of a family of state-of-the-art GPON SoCs, to be marketed as part of iGES (iamba GPON Eco-System), an end-to-end GPON solution suite for Telecommunication Equipment Manufacturers (TEMs) and Original Design Manufacturers (ODMs).

Combining iamba’s technological leadership in GPON with K-micro’s unique
burst mode clock data recovery (BM-CDR) technology and ASIC design expertise, the two companies are introducing innovative, high-performance and highly integrated SoCs for Optical Network Termination (ONT) and Optical Line Termination (OLT) applications. The SoC solutions include the iSN1000, a family of ONT SoCs for Single Family Unit (SFU), Small Business Unit (SBU) and Multi Dwelling Unit (MDU) applications and the iSL2404, a unique quad-PON OLT SoC for Central Office (CO) Access platforms.

The iSN1000 ONT SoCs are based on a unique multi-core processor architecture and include low jitter SERDES iamba’s GPON MAC Module (iGMM), and iamba’s unique Traffic Pump Module (iTPM) delivering full 1Gbps wire-speed data at all packet sizes. The iSN1000 line is comprised of versions optimized for SFU, SBU and MDU applications and is supported by system level software packages covering all management, VoIP, IPTV and legacy services.

The iSL2404 is a quad-PON OLT SoC, which supports 128 ONTs per PON, forward error correction (FEC) and advanced encryption standard (AES). The device, based on a unique multi-core processor architecture, also supports a powerful iamba Dynamic Bandwidth Allocation (iDBA) function that maximizes the bandwidth utilization of the PON interface. The iSL2404 is based on the iSL2402 design, currently in use by a number of Tier-1 TEMs and has been successfully tested by leading carriers in the United States, Europe and Asia.

K-micro’s Burst Mode Clock and Data Recovery (BM-CDR) technology has been integrated into the new iSL2404. The BM-CDR technology has been successfully integrated in two previous generations of products: the first-generation “Copper Tub” (CT1) that runs at 1.244/1.244 Gbps, and the more recent CT2 that runs at 2.488/1.244 Gbps. The design supports data bursts of variable size with minimum spacing, without loss of lock, and incorporates a variety of advanced features to support functions such as optoelectronics control, user defined fast lock window and chatter suppression. Implementation of this functionality in a pure CMOS process in a single chip minimizes power dissipation and device cost.

Continuity Software™, a leading provider of Disaster Recovery Management (DRM) solutions, announced it has launched operations in the United States, with a Boston headquarters office and a New York sales office, to support the data protection needs of U.S. customers. In conjunction with the U.S. company launch, the company formally introduced its RecoverGuard™ software, replication infrastructure gaps and configuration vulnerabilities detection solution.

RecoverGuard software is a groundbreaking Disaster Recovery Management (DRM) solution that detects gaps (i.e., configuration errors) and infrastructure vulnerabilities in real-time, in order to eliminate the risk of data loss or corruption in the face of a natural or manmade disaster. RecoverGuard’s unique ability to understand the relationships and interdependencies between IT infrastructure elements and the disaster recovery (DR) replication environment ensures that all production configuration changes are successfully applied to the remote hot site. With RecoverGuard, customers can now automate and validate the most critical aspect of their DR environment – ultimately ensuring their business protection goals.

BioLineRx, Israel’s leading drug development company announced the launch of its Early Development Program (EDP), a new strategic initiative to provide funding for early stage research and development of innovative therapeutics that have not yet achieved in-vivo proof of concept.
EDP is funded by a $6 million grant from Pan Atlantic Bank and Trust Ltd. (a wholly owned subsidiary of FCMI Financial Corporation, a Canadian company controlled by Albert D. Friedberg and members of his immediate family) and BioLineRx. The EDP grant is in addition to the $9 million invested in BioLineRx by Pan Atlantic in a private placement in January of this year.

“We are pleased to introduce this program for the development of promising early stage therapeutic research, which will enable us to both support and benefit from excellent early stage research originating from leading universities and research institutions,” commented Morris C. Laster, M.D., chief executive officer of BioLineRx. "The EDP will also provide us with an additional source for feeding our growing therapeutic pipeline, which currently consists of 14 compounds in various stages of clinical and pre-clinical development."

"We are very excited about the launch of EDP," added Albert D. Friedberg, President of FCMI Financial. "We searched for the best way to support outstanding early stage life science research and believe that BioLineRx is the best team to realize to the fullest the medical and business potential in the creative work done by academia primarily in Israel and other countries as well."

EDP combines the cutting-edge research performed in leading research institutions with BioLineRx's proven expertise in the accelerated advancement of drugs into the clinic and beyond. The program also provides a unique opportunity for researchers and scientists to see their early stage inventions advance rapidly through the professional drug development process.